We are live on ! Find out more
APTO

Aptose Biosciences, Inc.
APTO

Delisted

APTO was delisted on the 1st of April, 2025.

Back to rankings

44 hedge funds and large institutions have $13.5M invested in Aptose Biosciences, Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $13.4M → $13.5M (+$98.2K)

6% less funds holding

Funds holding: 47 → 44 (-3)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

58% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 12

Holders
44
Holders Change
-3
Holders Change %
-6.38%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
12
Closed
5
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$24K

Top Buyers

Rank Fund Capital Flow
1
SPC
Sigma Planning Corp
Michigan
+$241K
2
Jane Street
Jane Street
New York
+$7.84K
3
Morgan Stanley
Morgan Stanley
New York
+$4.94K
4
UBS Group
UBS Group
Switzerland
+$2.61K
5
JAWM
J. Arnold Wealth Management
Ohio
+$1.45K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$693K
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$214K
3
CC
Carlson Capital
Texas
-$200K
4
Renaissance Technologies
Renaissance Technologies
New York
-$107K
5
Millennium Management
Millennium Management
New York
-$107K

APTO Hedge Fund Activity: Q1 2023 in Review

44 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2023, worth a combined $13.5M — up 0.73% from $13.4M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of APTO and 4 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 5 added.

The largest buyer was Sigma Planning Corp, adding an estimated $241K. The largest seller was Nantahala Capital Management, cutting an estimated $693K.

  • 44 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2023, down from 47 in Q4 2022.
  • Funds reported $13.5M of Aptose Biosciences, Inc. stock for Q1 2023, up 0.73% quarter-over-quarter.
  • 4 funds opened new Aptose Biosciences, Inc. positions in Q1 2023 and 5 closed out, a net change of -1 holder.
  • The largest Aptose Biosciences, Inc. buyer in Q1 2023 was Sigma Planning Corp, an estimated $241K added.
  • The largest Aptose Biosciences, Inc. seller in Q1 2023 was Nantahala Capital Management, an estimated $693K sold.

Based on aggregated 13F filings for Q1 2023.